Lacosta Carver, APRN
Family · Albany, KYNPI 1053704403
Payments from drug & device makers
Across 95 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$334
- AstraZeneca$143
- Lilly USA, LLC$115
- Pfizer$110
- GSK$105
- Dexcom, Inc.$98
- plus $604 from 19 others
What the payments were for
- Food & beverage$1,509100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $334 |
| AstraZeneca | 8 | $143 |
| Lilly USA, LLC | 8 | $115 |
| Pfizer | 6 | $110 |
| GSK | 6 | $105 |
| Dexcom, Inc. | 6 | $98 |
| Novo Nordisk | 5 | $68 |
| Boehringer Ingelheim | 4 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Novartis | 3 | $47 |
| Exact Sciences | 3 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Abbott | 2 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Amgen | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Sobi, Inc | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$1,509 in reported general payments places this provider in the 70th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 57 | $68,877 |
| OzempicSemaglutide | 61 | $63,026 |
| EliquisApixaban | 66 | $42,195 |
| XareltoRivaroxaban | 40 | $24,127 |
| LinzessLinaclotide | 41 | $23,148 |
| JanuviaSitagliptin Phosphate | 28 | $18,073 |
| TrulicityDulaglutide | 18 | $17,161 |
| FarxigaDapagliflozin Propanediol | 20 | $16,285 |
| VraylarCariprazine Hcl | 11 | $15,055 |
| RexultiBrexpiprazole | 12 | $14,781 |
| JardianceEmpagliflozin | 12 | $13,062 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $10,182 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $8,885 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $8,473 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $115 | $86,03875 claims |
| Novo NordiskOzempic | $68 | $63,02661 claims |
| PfizerEliquis | $110 | $42,19566 claims |
| AbbVieLinzess, Vraylar, Synthroid, Armour Thyroid | $334 | $40,89995 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $143 | $29,67344 claims |
| Johnson & JohnsonXarelto | $16 | $24,12740 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $53 | $21,94731 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $17 | $14,78112 claims |
| GSKTrelegy Ellipta | $105 | $10,18218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,374 family providers in Kentucky.
Other family in Albany
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.